Relief Therapeutics Holding SA Share Price

Equities

RLF

CH1251125998

Biotechnology & Medical Research

End-of-day quote Swiss Exchange 23:00:00 24/04/2024 BST 5-day change 1st Jan Change
1.25 CHF -6.72% Intraday chart for Relief Therapeutics Holding SA -4.58% -37.19%

Financials

Sales 2021 3.32 3.03 265.85 Sales 2022 6.08 5.55 486.8 Capitalization 132M 121M 10.56B
Net income 2021 -34M -31.05M -2.72B Net income 2022 -50M -45.66M -4B EV / Sales 2021 70,411,981 x
Net cash position 2021 40.5M 36.99M 3.24B Net cash position 2022 14.89M 13.6M 1.19B EV / Sales 2022 19,251,190 x
P/E ratio 2021
-6.44 x
P/E ratio 2022
-2.5 x
Employees 69
Yield 2021 *
-
Yield 2022
-
Free-Float 65.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.72%
1 week-4.58%
Current month-3.85%
1 month-9.42%
3 months-23.87%
6 months-35.90%
Current year-37.19%
More quotes
1 week
1.21
Extreme 1.21
1.35
1 month
1.20
Extreme 1.2
1.38
Current year
1.20
Extreme 1.2
1.99
1 year
1.20
Extreme 1.2
15.00
3 years
1.20
Extreme 1.2
104.80
5 years
0.32
Extreme 0.32
320.00
10 years
0.32
Extreme 0.32
320.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 27/01/22
Director of Finance/CFO - -
Chairman 46 24/05/16
Members of the board TitleAgeSince
Chairman 46 24/05/16
Chief Operating Officer - 26/05/21
Director/Board Member 56 16/12/20
More insiders
Date Price Change Volume
26/04/24 1.3 +4.00% 1,665
25/04/24 1.25 -6.72% 11,808
24/04/24 1.34 +4.28% 24,512
23/04/24 1.285 +1.98% 31,008
22/04/24 1.26 -3.82% 13,204

End-of-day quote Swiss Exchange, April 24, 2024

More quotes
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
More about the company

Chiffre d''affaires - Rate of surprise